key: cord-1041009-ipjejsnm
authors: Chapman, Asheley P.; Tang, Xiaoling; Lee, Joo R.; Chida, Asiya; Mercer, Kristina; Wharton, Rebekah E.; Kainulainen, Markus; Harcourt, Jennifer L.; Martines, Roosecelis B.; Schroeder, Michelle; Zhao, Liangjun; Bryksin, Anton; Zhou, Bin; Bergeron, Eric; Bollweg, Brigid C.; Tamin, Azaibi; Thornburg, Natalie; Wentworth, David E.; Petway, David; Bagarozzi, Dennis; Finn, M.G.; Goldstein, Jason M.
title: Rapid Development of Neutralizing and Diagnostic SARS-COV-2 Mouse Monoclonal Antibodies
date: 2020-10-14
journal: bioRxiv
DOI: 10.1101/2020.10.13.338095
sha: 68a2c0578f82114589117d0b175619f534ed2b85
doc_id: 1041009
cord_uid: ipjejsnm

The need for high-affinity, SARS-CoV-2-specific monoclonal antibodies (mAbs) is critical in the face of the global COVID-19 pandemic, as such reagents can have important diagnostic, research, and therapeutic applications. Of greatest interest is the ~300 amino acid receptor binding domain (RBD) within the S1 subunit of the spike protein because of its key interaction with the human angiotensin converting enzyme 2 (hACE2) receptor present on many cell types, especially lung epithelial cells. We report here the development and functional characterization of 29 nanomolar-affinity mouse SARS-CoV-2 mAbs created by an accelerated immunization and hybridoma screening process. Differing functions, including binding of diverse protein epitopes, viral neutralization, impact on RBD-hACE2 binding, and immunohistochemical staining of infected lung tissue, were correlated with variable gene usage and sequence.

Previous beta-coronavirus outbreaks from SARS-CoV (2003) and MERS-CoV (2008) highlighted the value of novel antibody development in the rapid diagnosis of infection. Studies of these earlier coronaviruses have informed current SARS-CoV-2 vaccine design, especially concerning epitope motifs to target for virus neutralization. The ~300 amino acid receptor binding domain (RBD) within the S1 subunit of the spike protein (Fig. 1a) is particularly significant, as it contains the five contact residues (L455, F486, Q493, S494, N501) 1,2 previously shown to be important for viral entry through interactions with the ACE2 receptor present on many cell types, especially lung epithelial cells. 3 In order to target this key polypeptide motif, we employed three different immunogens: a commercially-available S1 domain (residues 1-681) 4 with C-terminal histidine tag (designated His-S1), a commercial RBD sequence (residues 319-541 4 ) fused at the C-terminus with a mouse IgG1 Fc domain (designated mFc-RBD) (Fig 1a) , and the noncovalent complex of mFc-RBD with the PP7 bacteriophage virus-like particle (VLP) engineered to express two sequential Fc-binding Z-domains at 120 places on the VLP exterior surface (designated PP7zz). 5 The last construct provided a large (Fig. 1b) polyvalent display of receptor binding domains which we hoped would productively engage immune cells and stimulate affinity maturation. The use of Fc-tagged antigens is well known to increase antigen uptake and processing, 6 including many examples with viral antigens. [7] [8] [9] [10] [11] While the virus-like particles used here were regarded as self-adjuvanting, 12, 13 the recombinant S1 and RBD proteins were usually augmented by TiterMax ® Gold emulsion adjuvant. Three sets of BALB/c mice were immunized with different accelerated vaccination schedules (Fig. 1c) , characterized by the use of only the recombinant His-S1 domain (Series 1), a combination of mFc-RBD and PP7zz-displayed mFc-RBD immunogens beginning with mFc-RBD (Series 2), and the VLP-displayed mFc-RBD with a final focusing boost of His-S1 (Series 3).

Individual mice or pairs of mice were chosen for maximum immune response as indicated by serum antibody titer (Fig. 1d,e) , rather than larger cohorts as would be necessary to determine reproducibility and mechanistic trends. Recombinant spike subunit 1 protein (His-S1, residues 1-681) or S1 Receptor Binding Domain (mouse Fc-RBD, residues 319-541, ACE2 contact residues in purple; PDBID: 6vxx) antigens. b, VLP display of Fc-tagged antigens using the PP7 particle bearing 120 ZZ-domains; a 1:1 mass ratio of mFc-RBD and VLP provides a Fc:ZZ molar ratio of approximately 0.8. Rh = hydrodynamic radius measured by dynamic light scattering in phosphate buffer. c, Vaccine schedule and strategy. Six-week old female BALB/c mice (n = 3 per group) were immunized with primary antigen and adjuvant on day 0 followed by boosts on days 14 and 27. Blood was collected for ELISA on days 0, 14, 21 and 30. d, ELISA responses for serum dilutions against plated His-S1 protein from the sacrificed mice at day 30. e, Titer values from ELISA analysis as in panel d, against plated His-S1 or spike ectodomain protein. Immunization series defined in panel c; a and b designate different mice within that series. Experimental error represents standard deviation.

Splenocyte harvest (day 30) and myeloma fusion (Extended Data Fig. 2a, b) were followed by robotic selection of high IgG secretors from 3D semi-solid culture. Enzyme-linked immunosorbent assay (ELISA) analysis of supernatants from individual cultures of these cells against immobilized antigenic protein (recombinant His-S1 or engineered SARS-CoV-2 spike ectodomain protein, 14, 15 presumed to exist as monomer and noncovalent trimer, respectively) revealed the series 2 immunization protocol featuring mFc-RBD primary immunization to be superior in producing SARS-CoV-2 relevant antibodies (Fig. 2a, Extended Data Fig. 2b ). Each of 159 spike-binding mAbs selected by ELISA (157 from series 2, two from series 3) were further characterized by semi-quantitative measurement of the binding strength of purified antibody or hybridoma supernatant to soluble spike ectodomain using biolayer interferometry (BLI). Twelve of these showed apparent avidity (reported as inverse of the adsorption constant, 1/Kads) better than 1 nM and seventeen exhibited 1/Kads values between 1 and 10 nM (Fig. 2b, Table 1 ). Four mAbs demonstrating markedly lower avidity by BLI (3D2, 3G6, 3B1, 3A6) were also carried forward based on their demonstration of interesting or unusual properties as described below. All of the 33 selected mAbs were IgG1 (k light chain), showed strong binding to both plated S1 subunit and spike ectodomain proteins, with overall larger signals for the latter under otherwise identical ELISA conditions ( Figure 2c , Table S1 ), and bound (in hybridoma supernatant) inactivated (gamma-irradiated) SARS-CoV-2 virus (Fig. 2d) . The binding of serum, supernatants, and antibodies to the ectodomain were not found to be consistently affected by storage or incubation of the target protein at various temperatures, a concern raised by a recent report that the structure of the ectodomain may be cold-sensitive (Extended Data Fig. 3 ). 16 Figure 2 . Characterization of anti-SARS-COV-2 antibodies as supernatants from hybridoma clones. a, Antigen specificity of antibody binding from IgG-secreting hybridomas chosen from Series 1-3 immunization schedules. Numbers inside circles are total clones selected, numbers within each portion reflect binding selectivity. b, Distribution of affinities of the 33 selected clones as measured by BLI. c, Binding to two different Spike recombinant proteins (ecto Spike trimer and S1 polypeptide) as determined by ELISA. d, Binding of antibodies to g-irradiated WA-SARS-CoV-2 by ELISA (15 ng/mL virus plated, supernatant undiluted, secondary antibody = goat anti-mouse IgG HRP conjugate).

Variable-region sequencing showed three sets of identical mAbs: 3A2/3A7/3F5 (plus 3C6, identical in the heavy chain but with some variations in the light chain, corresponding to modest functional differences as described below); 3C4/3E4, and 3E1/3D3/9F2. Since the spatial separation of cells in the 3D culture matrix usually far exceeded the resolution of the clone-picking apparatus, it is unlikely that these sets of identical antibodies arose from the same hybridomas.

(The lone exception was 3E1 and 9F2, which originated from same clone sampled twice, Extended Data Fig 2b. ) Overall, the sequences of these high-affinity antibodies clustered into several discreet groups based on heavy-or light-chain similarities (Fig. 3a, b) . The most diverse region in terms of length and amino acid composition proved to be heavy-chain CDR3 (Fig. 3c,   d) , whereas greater diversity in gene usage was observed in the light chain (Fig. 3e) . Gene clustering was found to have relevance to functions described below. Thus, neutralization (mAb groups 1-3) was associated primarily with the presence of IGHV1 and 8, and with IGKV1, 3, and 6; the large non-neutralizing Group 3 all shared the IGHV14-1 gene and about half also incorporated IGKV6-32.

The diversity of epitopes recognized in binding the spike ectodomain was assessed by pairwise competitive binding measurements using BLI (Fig. 3f) . Low values indicated competition of the two antibodies for identical, nearby, or allosterically-related epitopes, whereas large BLI signals indicated non-competitive antibody association to different epitopes. Six major binding groups were thereby identified (Fig. 3e , Extended Data Fig. 5-7) . Some correlation was observed with sequence overlap (as shown by the group labels in Fig. 3a, b) , but a much greater degree of correlation was observed to heavy-chain sequences and specific IGHV and IGKV combinations (noted above and Extended Data Fig. 5 ), and to other functional assays. * Identical amino acid sequences (see Figure 3a and b), so measured avidity treated as average (approx. 1.7 nM) ** Identical amino acid sequences, so measured avidity treated as average (approx. 1. The effect of the selected mAbs on the binding of the SARS-CoV-2 RBD to the human ACE2 receptor was determined by two in vitro methods: a direct binding measurement using both longer (residues 1-740 = nearly the full polypeptide, referred to here as the "full-length" protein) and

shorter (residues 1-614, lacking the C-terminal collectrin-like domain, termed "truncated") ACE2

constructs, and a split luciferase assay employing the truncated version ( Fig. 4a , b). Ten mAbs (3A2/3A7/3F5 = identical sequence, 3C6, 3B3, 3H6, 3H2, 3F2, 3G1, and 3A6) were found to strongly inhibit RBD binding to both versions of hACE2 in dose-dependent fashion. Eight of these antibodies (3A2/3A7/3F5, 3B3, 3H6, 3H2, 3F2, and 3G1) plus two others (3G7, 3C2, also inhibitors of the RBD-ACE2 interaction but with a different profile, discussed below) exhibited potent neutralization of SARS-CoV-2-WA P#4, an early patient isolate, 17 in cell culture (Figure 4c , Table S1 ). These results were supported by a second neutralization assay employing a GFP-expressing variant of SARS-CoV-2 18 (Fig. 4c) . Neutralizing (red) and IHC staining mAbs (blue) determined via functional assays ( Fig. 4 ) c,d, Distribution of CDR3 amino acid length in heavy (c) and light (d) chains of 32 SARS-COV-2 mAbs. e, IGHV and IGKV genes identified for mAbs from sequences in panels (a) and (b). mAb 5A1 was not sequenced. Antibody grouping includes sequence, epitope, and function-level characteristics. f, Representative assessment of competitive mAb binding to recombinant ectodomain immobilized to streptavidin-coated BLI sensor chips via Strep-tag ® sequence. Binding to the "primary" antibody was validated by BLI, followed by washing and exposure to the secondary antibody to generate the binding signal of interest.

Twenty-one other mAbs exhibited significant levels of apparent RBD/hACE2 antibodydependent binding enhancement with the truncated ACE2 receptor, but 17 of these had little or no effect on the interaction of RBD with full-length ACE2; the remaining 3 (3G7, 3C2, 3B4) showed moderate levels of full-length ACE2-RBD binding inhibition (Fig. 4a , f). Since the truncated ACE2 lacks the receptor's dimerization domain, 19 it is clear that these antibodies recognize different epitopes, and are distinct in functional class, from the strong inhibitors of RBD binding to both hACE2 constructs.

The in vitro split luciferase functional assay mirrored these binding results with several interesting exceptions. Thus, 3H6, 3G7, and 3C2 had strong effects on RBD-ACE2 direct binding but little influence on split luciferase readout; contrariwise, 3A1 and 5A1 inhibited the SARS-2 split luciferase reporter but did not inhibit direct binding. As described below, these functional oddities were matched by independently observed differences in competitive epitope binding. When the RBD component of the split luciferase assay was changed to the SARS-CoV-1 sequence, all but one strongly neutralizing antibody was shown to be selective for SARS-CoV-2 (Fig. 4f ). [One neutralizer (3H6) had no effect on the split luciferase assay, and one strong ACE2 binding inhibitor (3A6) was not neutralizing. The latter, interestingly, was the only mAb to inhibit RBD binding to both CoV-1 and CoV-2 ACE2 sequences and also had low overall binding affinity for the Based on sequence variations and epitope binning experiments (Fig 3) 23 Four mAbs (3B1, 3D2, 3F4, 3D1) were found to bind to a detectable degree to a synthetic biotinylated 15-mer peptide of the receptor binding motif covering amino acids 486-501 (Fig. 4d) , which contains four out of five key RBD-hACE2 contact residues. 1,2 None of these four antibodies are strongly neutralizing, suggesting that the linear (and presumably unstructured) peptide is not presented by the infectious virus.

Such a peptide motif, however, can apparently be presented when the virion is degraded.

Among our high-affinity mAb panel, we identified two (3D2 and 3D7) from a subset of 13 (including 3G7, 3F2, 5A1, 3A1, 3F1, 3B1, 3A6, 3G6) that preferentially stained SARS-CoV-2 viral spike protein in lung tissue from infected patients. These samples underwent standard fixation and subsequent heat treatment to expose antigen, likely in denatured form, at the surface (Fig. 4e ).

As noted above, these clones have functional characteristics opposite to those desired of a therapeutic molecule: they exhibited little or no detectable neutralization activity and enhanced binding of spike protein to the truncated ACE2 receptor. Heat-inactivated virions obtained from ATCC were recognized by ELISA by only 3H2 (Extended Data Fig. 4c ) among the mAbs described here.

Recognition of gamma-irradiated SARS-CoV-2-WA virions was also not uniform among mAbs having roughly equal avidities for the recombinant spike ectodomain protein, as illustrated by ELISA analysis of 15 antibodies in Fig. 4g . Representative dose-response analysis showed that, while both 3H2 and 3A2 were equivalently potent in in vitro neutralization, the former mAb generated significantly larger ELISA signals at equivalent concentrations (Fig. 4h ). This resulted in a limit of detection of gamma-inactivated particles using 3H2 that was lower by an order of magnitude (Fig. 4i) . While it is sometimes assumed that gamma-irradiation does not alter viral surface antigens, 24 this is not at all certain. 25 We are aware of no studies of this question for coronavirus.

In summary, immunization using Fc-domain (and virus-like particle assisted) display of the SARS-CoV-2 receptor binding domain, followed by rapid parallel hybridoma production and screening, provided a panel of binding agents with diverse and useful functions in the context of virus binding and infectivity. This approach is complementary to that of teams led by Crowe and

Walker, who isolated large panels of human anti-SARS-CoV-2 mAbs from B cells from infected patients. 26, 27 As in those reports, a large number (here, 29 out of 33) anti-SARS-CoV-2 monoclonal antibodies were obtained exhibiting low-nanomolar or better avidity for the target spike ectodomain, consistent with many other reports validating this protein as a viable immunological target. We identified three groups of neutralizing antibodies recognizing distinct epitopes on the RBD motif as inferred from sequence and competitive binding experiments (Fig.   3e , f; Extended Data Fig. 6, 7) . A fourth group, the largest in number, were not strongly neutralizing and had either no effect on, or enhanced in one assay, the recognition of human ACE2 by the recombinant RBD. A fifth functional group stained fixed and heat-treated lung tissue from infected COVID-19 patients. Each functional class was also largely distinctive in its epitope recognition and in its sequence.

General. Monoclonal antibody sequencing and functional tests were performed by blinded researchers. All data were processed and graphed using GraphPad Prism v.8.

We employed the stabilized prefusion spike construct of Graham and McLellan (designated "s2p" by those investigators, and "recombinant spike ecto" (r-spike ecto)

here. 15 This polypeptide lacks the transmembrane sequence of the natural virus, has a mutated furin cleavage site (RRAR to GSAS) to block proteolytic processing, and is capped at the C-terminus with a His8 tag followed by two Strep-Tag ® II sequences (WSHPQFEK) bridged by a flexible connector (GGGSGGGGSGGSA). according to the manufacturer's instructions. 29 RNA reverse transcription and first strand cDNA synthesis were carried out using chain-specific reverse primers 30 with ProtoScript® II First Strand cDNA Synthesis Kit (NEB). The resulting cDNA was used as template for preparing the sequencing library using 5' multiplex PCR as previously described. 31 The PCR products corresponding to the library amplification were purified on BluePippin with size cutoff around 500 bp. The gel purified amplification products were then indexed, purified, quantified, and validated according to instructions provided by the manufacturer (Illumina). The Illumina Version 3 (2 x 300 bp) sequencing kit was used to sequence the library, and sequencing data were processed using the MiXCR tool. 32

Anti-spike immune responses, antigen specificity of immunized mouse sera, and antigen recognition of hybridoma supernatants were analyzed by ELISA. His-S1 or ecto-spike proteins were plated on half-area high-binding 96-well polystyrene plates (Corning) at 1 µg/mL or 0.5 µg/mL, respectively, in PBS overnight at 4°C. Unbound protein was washed away with PBST (1x PBS with 0.5% Tween) followed by blocking with 1% casein (w/v) in PBS (VWR International, Radnor, PA) for 2 h at room temperature with mild shaking (55 rpm). Serum or supernatant samples were then incubated for 1 hr at room temperature with shaking, followed by washing with PBST. For serum titers, six dilutions of sera in blocking buffer were plated; for supernatant specificity and epitope mapping experiments, undiluted hybridoma supernatant was plated. Secondary reporter goat anti-mouse IgG HRP (Southern Biotech) was diluted (1:2500) in blocking buffer and incubated for 1 h at room temperature with shaking, followed by washing. Plates were developed by adding 1-step Ultra TMB (Fisher Scientific) for 30 s (serum) or 90 s (supernatant), followed by quenching with 2N H2SO4.

Absorbance (450 nm) was measured by platereader (Varioskan Flash, Thermo Fisher Scientific).

Titers were calculated by sigmoidal non-linear regression using GraphPad Prism v.8 analysis with log 10 serum dilution plotted against absorbance at 450 nm. Recombinant mNeonGreen SARS-CoV-2 reporter virus icSARS-CoV-2-mNG 18 was diluted to 2,000 TCID50/mL in infection media and an equal volume (60 µL) of the diluted virus was added to each well on the antibody dilution plates. Following 60 min incubation at room temperature, 100 µL of the virusantibody mixture from each well was transferred to corresponding wells on the cell plates, from which the original cell culture media were decanted right before the transfer. After 2 days of incubation at 37 o C with 5% CO2, plates were scanned with the EVOS FL Auto Cell Imaging System to identify cells emitting green fluorescence. The endpoint dilution at which antibodies were determined to be neutralizing was the highest dilution of antibody at which more than half of the wells were absent of green fluorescence.

Additional details regarding immunization, hybridoma generation and selection, in vitro characterization, sequencing, and competitive epitope binding are provided in the accompanying file.

Structural basis of receptor recognition by SARS-CoV-2

Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

A new coronavirus associated with human respiratory disease in China

Engineering the PP7 Virus Capsid as a Peptide Display Platform

Fc fusion as a platform technology: potential for modulating immunogenicity

F(c)gammaRI-targeted fusion proteins result in efficient presentation by human monocytes of antigenic and antagonist T cell epitopes

Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine

A neonatal Fc receptor-targeted mucosal vaccine strategy effectively induces HIV-1 antigen-specific immunity to genital infection

Adjuvant-Free Immunization with Hemagglutinin-Fc Fusion Proteins as an Approach to Influenza Vaccines

Evaluation of ebolavirus glycoprotein Fc fusion protein as a subunit vaccine (P4417)

Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns

Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune System

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Cold sensitivity of the SARS-CoV-2 spike ectodomain

Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States

An Infectious cDNA Clone of SARS-CoV-2

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the Octet

Bio-Layer Interferometry Analysis of the Target Binding Activity of CRISPR-Cas Effector Complexes

Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Inactivation of Lassa, Marburg, and Ebola Viruses by Gamma Irradiation

Preserving Immunogenicity of Lethally Irradiated Viral and Bacterial Vaccine Epitopes Using a Radio-Protective Mn 2+ -Peptide Complex from Deinococcus

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

Broad neutralization of SARS-related viruses by human monoclonal antibodies

The salt-sensitive structure and zinc inhibition of Borrelia burgdorferi protease BbHtrA

Phage Display Analysis of Monoclonal Antibody Binding to Anthrax Toxin Lethal Factor

Cloning and expression of murine Ig genes from single B cells

High-Quality Library Preparation for NGS-Based Immunoglobulin Germline Gene Inference and Repertoire Expression Analysis

MiXCR: software for comprehensive adaptive immunity profiling

Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association

We are grateful to Dr. Barney Graham (Vaccine Research Center, NIAID) and Prof. JasonMcClellan (University of Texas Austin) for the plasmid for the engineered spike ectodomain protein used in this work, 15 under a material transfer agreement with the NIH. We also thank Jeff Noble for assistance with terminal mouse bleeds. Funding: This work was funded by the Centers for Disease Control and Prevention, and by the endowment for the James A. Carlos Family Chair for Pediatric Technology at the Georgia Institute of Technology.